{
    "organizations": [],
    "uuid": "39ac61718ddc0331b5fb33dd55b3072d13efbd2c",
    "author": "",
    "url": "https://www.reuters.com/article/brief-zealand-announces-successful-end-o/brief-zealand-announces-successful-end-of-phase-2-meeting-with-fda-on-glepaglutide-for-short-bowel-syndrome-idUSASO0003UM",
    "ord_in_thread": 0,
    "title": "BRIEF-Zealand Announces Successful End-Of-Phase 2 Meeting With FDA On Glepaglutide For Short Bowel Syndrome",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 26 (Reuters) - Zealand Pharma A/S:\n* ZEALAND ANNOUNCES SUCCESSFUL END-OF-PHASE 2 MEETING WITH FDA ON GLEPAGLUTIDE FOR SHORT BOWEL SYNDROME\n* SAYS PIVOTAL PHASE 3 TRIAL IS ON TRACK FOR INITIATION IN Q3 2018\n* ZEALAND EXPECTS TO INITIATE PIVOTAL PHASE 3 TRIAL IN Q3 2018\n* SCIENTIFIC ADVICE WITH EUROPEAN MEDICINES AGENCY (EMA) IS ONGOING WITH AN EXPECTED OUTCOME BY MID-2018 Source text for Eikon:\n ",
    "published": "2018-04-26T07:57:00.000+03:00",
    "crawled": "2018-04-26T08:21:45.004+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "zealand",
        "pharma",
        "zealand",
        "announces",
        "successful",
        "meeting",
        "fda",
        "glepaglutide",
        "short",
        "bowel",
        "syndrome",
        "say",
        "pivotal",
        "phase",
        "trial",
        "track",
        "initiation",
        "q3",
        "zealand",
        "expects",
        "initiate",
        "pivotal",
        "phase",
        "trial",
        "q3",
        "scientific",
        "advice",
        "european",
        "medicine",
        "agency",
        "ema",
        "ongoing",
        "expected",
        "outcome",
        "source",
        "text",
        "eikon"
    ]
}